Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3DM8Y
|
|||
| Drug Name |
AMG 609
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04857606) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health. | |||
| REF 2 | Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022 Jan;126:154925. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.